Oxford Biomedica has signed a new three-year deal to make AstraZeneca’s Covid-19 vaccine beyond this year when the original agreement expires, the company said on Friday.
The Oxford-based gene and cell therapy group said it expected to record about £30m in revenue from the contract in the current financial year.
Under the new deal, manufacturing of vaccines at Oxford manufacturing facility, Oxbox, will be available to AstraZeneca on an as-needed basis beyond 2022.
